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Summary A synergistic effect with respect to inactivation of human NHIK 3025 cells cultured in vitro was
displayed when treatment with cis-dichlorodiammineplatinum(II) (cis-DDP) and the mitotic inhibitor 1-
propargyl-5-chloropyrimidin-2-one (NY 3170) were given in simultaneous combination. Cell inactivation was
measured by loss of colony-forming ability. Treatment with NY 3170 alone produced no significant
inactivation at concentrations up to 2mM. However, treatment with NY 3170 in combination with cis-DDP
induced increased cell inactivating effects equal to a doubling of either the concentration of cis-DDP or
treatment time. Scheduling of NY 3170 treatment in relationship to a 1 h cis-DDP pulse revealed that
synergism occurred only when the two drugs were present simultaneously. The inactivating effect of lOpM
cis-DDP in combination with 2mM NY 3170 given to synchronized NHIK 3025 cells at various stages of the
cell cycle was also determined. For cells treated in S or in G2+M cell survival was reduced by a factor of 5
after a I h treatment with the drug combination as compared to similar treatment with cis-DDP alone.
The cells appeared to be most sensitive at the time of initiation of DNA synthesis. Here cell survival was
reduced by a factor of 100 following treatment with the drug combination than following treatment with cis-
DDP alone. Measurement of cell-associated platinum by atomic absorption spectroscopy indicated that
cellular uptake of cis-DDP was increased when NY 3170 was simultaneously present during drug treatment.
I-Propargyl-5-chloropyrimidin-2-one (NY 3170) is a mitotic
inhibitor which causes reversible metaphase inhibition in
cultured cells (Wibe & Oftebro, 1979). A sufficient, but
necessary prerequisite for metaphase inhibition is that the
drug be present during mitosis (Wibe et al., 1979). The
parent compound 5-chloropyrimidin-2-one (NY 3000) also
induces metaphase arrest in cultured cells (Wibe et al., 1978).
Both NY 3170 and NY 3000 are members of a new class of
mitotic inhibitors, called metahalones, which are based upon
a pyrimidine structure (Gacek et al., 1978). NY 3170 binds
weakly to tubulin, the major protein of microtubules and the
spindle apparatus (Dornish et al., 1984a), and is a
competitive inhibitor of colchicine binding to tubulin
(Dornish & Oftebro, 1983; Dornish et al., 1984a). The
combination of NY 3170 and vincristine has shown more
than additive effects with respect to cell inactivation when
human cells of the cell line NHIK 3025 were treated with
both agents (Wibe, 1980).
Cis-Dichlorodiammineplatinum(II) (cis-DDP) is known to
act synergistically when administered in combination with
various chemotherapeutic drugs (Gale et al., 1977; Schabel et
al., 1979). Many pyrimidine compounds in combination with
cis-DDP have demonstrated increased cell inactivating effects
(Davidson et al., 1975). Pyrimidine bases and nucleosides
(Drewinko et al., 1980), I-,B-D-arabinofuranosylcytosine
(Bergerat et al., 1981; Drewinko et al., 1980; Schabel et al.,
1979) and 5-aza-2'-deoxycytidine (Vesely, 1982) in
combination with cis-DDP have displayed marked synergistic
effects both in vivo and in vitro. The exact mechanism
responsible for synergism between pyrimidine compounds
and cis-DDP is not known although Drewinko et al. (1980)
have found an increase in the number of DNA cross-links
following cis-DDP+ 1-,B-D-arabinofuranosylcytosine com-
bination treatment.
This report presents results in which NY 3170 (a
pyrimidine and a mitotic inhibitor) in combination with cis-
DDP (a DNA damaging agent (Zwelling & Kohn, 1979;
Zwelling & Kohn, 1980)) displays synergistic cell inactivation
of human cells treated in culture.
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Materials and methods
Cell line and cell synchronization
NHIK 3025 cells originating from a human cervical
carcinoma in situ (Nordbye & Oftebro, 1969; Oftebro &
Nordbye, 1969) were cultivated as monolayers in medium
E2a (Puck et al., 1957) supplemented with 20% human and
10% horse serum (Gibco Europe Ltd., Renfrewshire,
Scotland, UK). Under growth conditions used, the mean
cell-cycle phase durations are 6.5h for GI, 8h for S and
2.5 h for G2. Mitosis lasts for I h. The median cell-cycle time
is 18 h (Pettersen et al., 1977). Cells were synchronized by
mitotic selection (Pettersen et al., 1977) and seeded
immediately into 25cm2 plastic flasks (Falcon 3013, Falcon
Plastics, Oxnard, CA, USA). All experiments involving
synchronized cells were performed in a 37°C incubator room.
The entrance of cells into the various cell-cycle phases was
determined by flow cytometry of mithramycin-stained cells
as described by Lindmo and Pettersen (1979) and Pettersen
et al. (1983). Cell division was recorded in a separate 25cm2
flask where fields of - 100 cells were followed micro-
scopically. The time of each cell division was recorded.
Cell survival
The inactivating effect of drugs was determined using
asynchronous NHIK 3025 cells seeded onto 60 x 15mm style
plastic petri dishes (Falcon 3002). A known number of cells
was seeded in each of 5 replicate dishes and allowed to
attach for 2h. Drug-containing medium was then added and
incubation continued for 1 h. Finally the drug-containing
medium was removed, the dishes were rinsed with warm
(37°C) Hanks' balanced salt solution and fresh medium was
added. Incubation of cells for colony formation was for 12-
14 days in a 5% CO2 incubator holding 37°C. Medium was
changed 7 days after the experiment was initiated. Colonies
of cells were fixed in ethanol and stained with methylene
blue. Colonies consisting of over 40 cells were counted.
For experiments involving synchronized cells, each data
point represents counts from 4 replicate flasks. Cells were
seeded into flasks immediately after mitotic selection and
allowed to attach for 2h before I h drug combination
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treatments were initiated at various times after mitotic
selection. Cells were then washed with warm (37°C) PBS
(NaCl 8,000mg1- 1; Na2HPO4 2H2O 1,150mg1-; KH2PO4
200mg 1- 1; KCl 200mg1- 1) and fresh medium added.
Incubation for colony formation was for 10-12 days at 37°C.
Flasks were flushed with 5% CO2 in air whenever opened.
Colonies were fixed and stained as above.
Atomic absorption spectroscopy
Analysis of cell-associated platinum was performed using a
Varian SpectrAA-30 atomic absorption spectrometer fitted
with a GTA-96 graphite tube atomizer. Instrument control
and data acquisition was by Varian Atomic Absorption
Software. Automatic background correction with a
modulated deuterium lamp was utilized. Cells were loosened
from flasks by trypsin treatment and counted. A volume
equivalent to 2 x 106 cells was pipetted into conical
centrifuge tubes, three replicate tubes for each drug
concentration. The tubes were centrifuged and cells were
resuspended in drug-containing medium, usually 3ml/tube.
The cells were incubated with drugs at 37°C and held in
suspension by using a rotary rack. After treatment the cells
were centrifuged and washed in phosphate-buffered saline.
The cell pellet was taken up into 1001[ concentrated HNO3.
Following overnight oxidation of organic material, 100 l
H20 was then added to each tube. Aliquots of 25pl
(representing 250,000 cells) were placed in a graphite tube
and the atomic absorption signal measured at 265.9 nm
following atomization of the sample was registered. Platinum
content was quantitated by running a calibration curve
immediately before the samples.
Drugs
Cis-dichlorodiammineplatinum(II) was purchased from
Sigma Chemical Co., St. Louis, MO, USA. 5-Chloro-
pyrimidin-2-one and 1-propargyl-5-chloropyrimidin-2-one
(Figure 1) were provided by Prof. S. Laland, Department of
Biochemistry, University of Oslo, Oslo, Norway. Drug
solutions were made in phosphate-buffered saline or Hanks'
balanced salt solution and sterile filtered. Drug combinations
were mixed immediately before use using stock solutions
diluted in medium E2a.
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Figure 1 Structure of 5-chloropyrimidin-2-one (NY 3000) and
I-propargyl-5-chloropyrimidin-2-one (NY 3170).
Results
Figure 2 shows the surviving fraction of asynchronous
(exponentially growing) NHIK 3025 cells following a I h
treatment with cis-DDP or cis-DDP in combination with
2 mm NY 3170 as a function of the concentration of cis-
DDP. NY 3170 alone has little or no effect on the survival
of exponentially growing cells after such a short treatment
period (Wibe & Oftebro, 1979). The data presented in Figure
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Figure 2 Surviving fraction of asynchronous NHIK 3025 cells
as a function of the concentration of cis-DDP (Li) or cis-
DDP+2mM NY 3170 (A). Single cells were plated on plastic
dishes 2h before medium with the appropriate concentration of
drugs was added. Following a 1 h incubation period, the dishes
were rinsed with warm (37°C) Hanks' balanced salt solution,
then fresh medium was added. The experimental points represent
the mean colony count from 5 replicate dishes. S.e. is represented
by vertical bars when exceeding the size of the symbols.
2 indicate that the simultaneous presence of 2mM NY 3170
resulted in an additional inactivating effect corresponding to
that which a doubling of the cis-DDP concentration would
give.
To study how the increase in cell inactivation by cis-DDP
depended upon the concentration of NY 3170, we performed
another set of experiments where exponentially growing cells
were treated with a combination of a fixed concentration of
cis-DDP (either 6 or 10yM) and NY 3170 at various
concentrations. The results are presented in Figure 3
together with data showing the surviving fraction following
treatment with NY 3170 alone. As demonstrated, cell
inactivation induced by cis-DDP alone was significantly
increased by the simultaneous presence of NY 3170.
As NY 3170 is synthesized from NY 3000 (Gacek et al.,
1979), the cell inactivating effect of a simultaneous
combination of 6 or 10,uM cis-DDP and various
concentrations of NY 3000 was also tested. The results in
Figure 4 clearly show that the simultaneous presence of up
to 5mM NY 3000 did not have any effect on cis-DDP-
induced cell inactivation. These results indicate the apparent
importance of the 1-propargyl side group present in NY
3170 for cis-DDP +NY 3170 synergism.
The synergistic effect of NY 3170 and cis-DDP as a
function of the duration of drug exposure is presented in
Figure 5. In these experiments, NHIK 3025 cells were
exposed to 10pM cis-DDP either alone or in combination
with 2mM NY 3170 for up to 4 h. While treatment with
2mM NY 3170 alone resulted in very small decreases in cell
survival, treatment with 10 M cis-DDP alone resulted in a
survival which decreased with increasing drug exposure
times. The simultaneous presence of 10,uM cis-DDP and
2 mm NY 3170 resulted in a large synergistic effect as
compared with that after cis-DDP alone. From the data, 1 h
treatment with 10pM cis-DDP+2mM NY 3170 resulted in
the same survival as 2 h treatment with 10 ,uM cis-DDP
alone.
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Figure 3 Surviving fraction of asynchronous NHIK 3025 cells
as a function of the concentration of NY 3170 (0), NY
3170+6p.tM cis-DDP (A), or NY 3170+10pM cis-DDP (A).
(U, El) represent 6puM or 10pM cis-DDP alone respectively.
Experimental conditions and s.e. as in Figure 2.
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Figure 5 Surviving fraction of asynchronous NHIK 3025 cells
as a function of the duration of drug treatment with 2mm NY
3170 (0), 10pM cis-DDP (C]), and 2mM NY 3170+10pM cis-
DDP (A). Single cells attached to plastic dishes were treated
with each drug or drug combination for the time indicated in the
figure. Drug treatment was terminated by removal of the drug-
containing medium, thereafter cells were washed in Hanks'
balanced salt solution and reincubated with fresh medium for
colony formation. Data from 5 replicate dishes were averaged for
each experimental point and s.e. is represented by vertical bars.
From Figure 6, NY 3170 (2mM) given simultaneously
with lOpM cis-DDP resulted in a cell survival reduced to
about one-tenth of that following treatment with cis-DDP
alone. When NY 3170 was added 0.5h later than cis-DDP
and thus overlapped the pulse of cis-DDP by only 0.5h, cell
survival was now reduced by only one-half of that after cis-
DDP alone. NY 3170 treatment immediately following the
, I I . | , | | cis-DDP pulse resulted in identical survival as did treat-
0 1 2 3 4 5 ment with cis-DDP alone. Further separation of NY 3170
Concentration of NY 3000 (mM) treatment after cis-DDP resulted in no further change in
survival.
4 Surviving fraction of asynchronous NHIK 3025 cells Figure 6 also shows that the same is true when NY 3170
function of the concentration of NY 3000 (0), NY treatment precedes the cis-DDP pulse. Identical survival was
6pM cis-DDP (A)., or NY 3000+101iM cis-DDP (A). measured until the treatment period for the two drugs mrepresent 6cpM or 10pM cis-DDP alone respectively, overlapped by 0.5 h. When NY 3170 treatment preceded that
mental conditions and s.e. as in Figure 2. of cis-DDP by 0.5 h, cell survival was again about one-half
that following cis-DDP treatment alone. Maximum
synergism with respect to cell inactivation thus occurs only
e experiments described thus far cis-DDP and NY when the two drugs are present simultaneously.
re added and removed simultaneously for combined To determine whether the increase in cis-DDP-induced cell
nt. We have also studied the combined effects when inactivation by NY 3170 was specific to any particular phase
rtment period for the two drugs were separated or of the cell cycle, we treated synchronized cell populations
ped only partially. The data in Figure 6 represents with 1 h pulses of 10 M cis-DDP alone or in combination
iexperiment where 1OjpM cis-DDP was present for with 2mm NY 3170 at various times after mitotic selection.
rizontal line marking from 0 to 1 h) and NY 3170 The results are shown in Figure 7. The synergistic effect of
was present as 1 h pulses either before, during, or NY 3170 in combination with cis-DDP was present
e cis-DDP treatment period. Survival is plotted as a throughout the cell cycle. Cells in late GI/early S appeared
of the time when NY 3170 was added. Cells treated to be the most sensitive where survival following treatment
pM cis-DDP alone (squares) or with 2mM NY 3170 with cis-DDP+NY 3170 was reduced by a factor of 100
ircles) are also shown. compared to that following cis-DDP treatment alone.
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Measurements of cell-associated platinum as performed by
use of flameless atomic absorption spectroscopy are shown
in Figure 8. The amount of cell-associated platinum in
asynchronous cells treated for I h (open squares) or 2 h
(filled squares) with cis-DDP increased as the concentration
of cis-DDP in cell culture medium increased. The
simultaneous presence of 2mM NY 3170, however, caused
an apparent doubling of the amount of cell-associated
platinum. After a 1 h treatment with cis-DDP in combination
with NY 3170 the amount of cell-associated platinum was
the same as after a 2h treatment with cis-DDP alone.
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Figure 6 Surviving fraction of asynchronous NHIK 3025 cells
treated with lOpM cis-DDP as a function of scheduling of I h
pulses of 2mM NY 3170 (A). (0) and (El) represent cell
survival after a 1 h pulse of 2mM NY 3170 alone or O 1pM cis-
DDP alone respectively. The horizontal bar represents the
treatment period for cis-DDP and the data points are plotted at
the time at which drug incubation began. Each experimental
point represents the mean of 5 replicate dishes. Vertical bars
represent s.e.
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Figure 7 Surviving fraction of synchronized NHIK 3025 cells
treated for I h with 2mM NY 3170 (0), 1O0pM cis-DDP (El), or
2mM NY 3170+ 10,uM cis-DDP (A) as a function of the time
after mitotic selection. Experimental points from 1 typical
experiment are plotted at the time at which drug incubation was
begun. The duration of the various cell-cycle phases for control
cells is indicated at the bottom of the figure. Each experimental
point represents the mean colony count from 4 replicate flasks.
The vertical bars represent s.e.
Furthermore, a 1 h drug combination treatment in S and G2
resulted in a reduction of cell survival to about one-fifth of
that following cis-DDP treatment alone.
Since the cell survival experiments indicated that treatment
of cells with cis-DDP in combination with NY 3170 mimic a
doubling of cis-DDP concentration, it was of interest to
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Figure 8 The platinum content in NHIK 3025 cells measured by
flameless atomic absorption spectroscopy as a function of the
concentration of cis-DDP in cell culture medium. Cells were
treated for 1 h (open symbols) or 2 h (filled symbols) with various
concentrations of cis-DDP alone (E], *) or in combination with
2 mm NY 3170 (A, A). The cells were then washed in PBS and
organic material in the cell pellet was oxidized with HNO3.
Platinum content in an aliquot representing 250,000 cells was
quantitated in triplicate for each drug concentration using the
265.9 nm absorbance line of platinum. Background correction
utilizing a modulated deuterium lamp was applied. Vertical bars
represent s.e.
Discussion
The mitotic inhibitor I-propargyl-5-chloropyrimidin-2-one
previously shown to exert a synergistic effect in combination
with vincristine (Wibe, 1980), also displayed synergism with
respect to cell inactivation when NHIK 3025 human cells
were treated with the drug in combination with cis-DDP
(Figures 2, 3 and 5). Analysis of the data in Figure 2 reveals
that the synergistic effect of NY 3170 is not of a dose-
modifying type, but that it increases with increasing
concentrations of cis-DDP. This is seen from Figure 2 by
calculating the ratio between the cis-DDP concentrations in
the absence and presence of NY 3170 at various survival
levels. While this ratio is 1.6 at the survival level of 0.5, it is
2.0 at the survival level of 0.001. Thus, NY 3170 does not
just increase the biological effects of cis-DDP by a certain
factor, but its effect depends upon the cis-DDP
concentration.
The maximal cis-DDP+NY 3170 synergism was found for
2mM NY 3170 (Figure 3) even though this concentration of
NY 3170 had no effect on cell inactivation alone. Higher
concentrations of NY 3170 alone did, however, inactivate
cells, thus 2mM was the limit of this investigation. With
respect to the duration of drug exposure, the presence of
2 mm NY 3170 together with cis-DDP caused similar cell
survivals as would a doubling of the time of treatment with
cis-DDP alone (Figure 5). Thus NY 3170 in combination
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with cis-DDP appears to cause cell inactivating effects that
mimic either a doubling of cis-DDP concentration or
treatment times.
The parent compound, 5-chloropyrimidin-2-one, also
possessing metaphase inhibitory properties (Gacek et al.,
1979; Wibe et al., 1978) did not display any effect on cis-
DDP-induced cell inactivation (Figure 4). The only
structural differences between these two molecules is the 1-
propargyl group present in NY 3170 (see Figure 1).
Results from scheduling NY 3170 administration (Figure
6) show that NY 3170 must be present simultaneously with
cis-DDP in order for the drug combination to exert a
synergistic cell inactivating effect. When NY 3170 treatment
either preceded or followed that of cis-DDP, cell survival
was identical to that following treatment with cis-DDP
alone. Slight overlapping of the two treatments resulted in a
reduction in cell survival by about one-half for the drug
combination than for cis-DDP alone. Simultaneous drug
treatment resulted in a reduction of cell survival to about
one-tenth of that following a I h pulse with cis-DDP alone.
From the above results two alternative assumptions are
possible: (1) cis-DDP and NY 3170 could react to form a
third compound of greater toxicity. (2) NY 3170 could
increase cellular uptake of cis-DDP.
Regarding the first assumption we know that NY 3170 is
able to penetrate cells quite readily (Wibe & Oftebro, 1981).
Intracellular cis-DDP forms an aquated platinum species
which react with nucleophilic sites (Zwelling & Kohn, 1979).
The carbon-carbon triple bond of the propargyl group of
NY 3170 may act as such a site. We have observed a
reaction between cis-DDP and NY 3170 (data not shown),
however, the kinetics of this reaction are too slow to explain
the observed synergism between the two drugs. Nevertheless,
we cannot rule out the possibility that just such a toxic
reaction may be responsible for the large increase in cell
inactivation seen when synchronized cells are treated in G1-
phase.
From Figure 7 one can see that treatment of synchronized
cells with cis-DDP alone caused an increased inactivation of
those cells in early GI-phase. Combination treatment of cis-
DDP together with NY 3170, however, caused a very large
inactivation of cells in late Gl-phase (i.e. from 6 to 8h after
mitotic selection) even though the two drugs were present for
only 1 h. Perhaps this difference in cell-cycle specific
inactivation may be due to just such a reaction between cis-
DDP and NY 3170. We know that initiation of DNA
synthesis in NHIK 3025 cells takes place from about 4 to 8 h
after the end of mitosis (unpublished results). Although an
unproven hypothesis, a possible reaction product between
cis-DDP and NY 3170 albeit in small quantities, could block
the initiation of DNA synthesis and cause irreversible
damage to cells in which DNA synthesis was already
initiated.
With respect to the second assumption we have previously
shown that benzaldehyde and the vitamin B6 aldehydes
pyridoxal and pyridoxal 5'-phosphate modulate cellular
toxicity of cis-DDP (Dornish et al., 1984b, 1986; Dornish &
Pettersen, 1985). In contrast to NY 3170, these aldehydes
induced a protective effect in combination with cis-DDP. As
it turned out, the protective effect was a result of reduced
cellular uptake of cis-DDP due to the aldehydes. It is not
known whether it is passive diffusion of cis-DDP (Gale et
al., 1973) or membrane-mediated transport (Byfield &
Calabro-Jones, 1981), or both, that is influenced by the
aldehydes. One can not exclude, however, that NY 3170
could have the opposite effect and increase cellular uptake of
cis-DDP due to a membrane effect leading to enhanced
cytotoxicity. Increased uptake of cis-DDP would also explain
why NY 3170 potentiates the cell inactivating effect of cis-
DDP in all stages of the cell cycle (Figure 7).
The results presented in Figure 8 confirm that, indeed, NY
3170 induces an increased uptake of cis-DDP into NHIK
3025 cells. Increased uptake of cis-DDP by NY 3170 is
transient as shown by scheduling experiments in Figure 6
where the drugs must be in simultaneous combination. This
could certainly be a membrane-mediated response to NY
3170. Finally, the structural moiety responsible for the
synergistic effect must reside within the propargyl side group
of NY 3170 since no such increase in cis-DDP uptake was
seen when cells were treated with NY 3000 and cis-DDP
(data not shown).
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